ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME

摘要

INTRODUCTION: Next-generation sequencing (NGS) is available for analysis of tumors in patients with glioblastoma multiforme (GBM) and can be used to match patients to clinical trials of agents that target specific alterations. We studied the relationship between molecular matching by NGS and treatment outcome in GBM patients treated on trials of targeted agents.METHODSPatients were adults with GBM who enrolled on clinical trials at our center. Patients underwent NGS with either FoundationOne (tissue) or Guardant360 (cell-free DNA) prior to enrollment on a trial. Treatment was classified as a direct match, indirect match, or non-match. Clinical benefit was defined as complete response, partial response, or at least 4 months on treatment without progressive disease by RANO criteria.